ID

22316

Description

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Study ID: 100151 Clinical Study ID: EGF100151 Study Title: A Phase III, Randomized, Open-label, Multicenter Study Comparing GW572016 and Capecitabine (XELODA) versus Capecitabine in Women with Refractory Advanced or Metastatic Breast Cancer Clinicaltrials.gov Identifier: NCT00078572 https://clinicaltrials.gov/ct2/show/NCT00078572 Procedure: Blood products Sponsor: GlaxoSmithKline Collaborators: N/A Phase: phase 3 Study Recruitment Status: Completed Generic Name: lapatinib Trade Name: Tyverb,Tykerb,Tycerb Study Indication: Breast Cancer; Neoplasms, Breast

Lien

https://clinicaltrials.gov/ct2/show/NCT00078572

Mots-clés

Versions (1)
  1. 29/05/2017 29/05/2017 -
Téléchargé le

29 mai 2017

DOI

Pour une demande vous connecter.

Licence

Creative Commons BY-NC 3.0
Modèle Commentaires :

Ici, vous pouvez faire des commentaires sur le modèle. À partir des bulles de texte, vous pouvez laisser des commentaires spécifiques sur les groupes Item et les Item.

Retour au modèle Commentaires
Groupe Item commentaires pour :

Item commentaires pour :

Vous devez être connecté pour pouvoir télécharger des formulaires. Veuillez vous connecter ou s’inscrire gratuitement.

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

Anglais

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

1 Formulaires  
Blood products
Description

Blood products

Alias
UMLS CUI-1
C0456388
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
Description

blood products

Type de données

text

Alias
UMLS CUI [1]
C0456388
Date started
Description

If YES, record below:

Type de données

date

Alias
UMLS CUI [1,1]
C0808070
UMLS CUI [1,2]
C0456388
Blood product
Description

Blood product

Type de données

integer

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0332307
Blood product, if other please specify
Description

Blood product

Type de données

text

Alias
UMLS CUI [1,1]
C0456388
UMLS CUI [1,2]
C0332307
Retour au début de la page

Similar models

XELODA and Lapatinib Advanced or Metastatic Breast Cancer Blood products NCT00078572

1 Formulaires
Name
Type
Description | Question | Decode (Coded Value)
Type de données
Alias
Item Group
Blood products
C0456388 (UMLS CUI-1)
Item
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
text
C0456388 (UMLS CUI [1])
blood products
Code List
Were any blood products given to the subject at any time between 2 weeks prior to the first dose of investigational product and 30 days post discontinuation of investigational product?
CL Item
Yes (Y)
CL Item
No (N)
Date started
Item
Date started
date
C0808070 (UMLS CUI [1,1])
C0456388 (UMLS CUI [1,2])
Item
Blood product
integer
C0456388 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Blood product
Code List
Blood product
CL Item
Whole blood (1)
CL Item
Red cells (2)
CL Item
Platelets - concentrate  (3)
CL Item
Plasma - FFP (4)
CL Item
Cryoprecipitate (5)
CL Item
Factor VIII (6)
CL Item
Other, specify text in the box (99)
Blood product
Item
Blood product, if other please specify
text
C0456388 (UMLS CUI [1,1])
C0332307 (UMLS CUI [1,2])
Retour au début de la page 

Contact

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Les champs marqués d’un * sont obligatoires.

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial